ALSUntangled #70: caffeine.

Autor: Hatch J; Medical College of Georgia at Augusta University, Augusta, GA, USA., Barkhaus P; Department of Neurology, Medical College of Wisconsin, Milwaukee, WI, USA., Barnes B; Department of Neurology, Medical College of Georgia, Augusta, GA, USA., Beauchamp M; Neurosciences Clinical Trials Unit, UNC, Chapel Hill, NC, USA., Benatar M; Department of Neurology, University of Miami, Miami, FL, USA., Bertorini T; Neurology Department, University of Tennessee Health Science Center, Memphis, TN, USA., Bowser R; Department of Neurology, Barrow Neurological Institute, Phoenix, AZ, USA., Bromberg M; Department of Neurology, University of Utah, Salt Lake City, UT, USA., Brown A; Department of Neurology, University of Miami, Miami, FL, USA., Mascias Cadavid J; ALS Department, Hospital Carlos III-La Paz, Madrid, Spain., Carter GT; Department of Rehabilitation, Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA., Cole N; Motor Neurone Disease Association, Northampton, UK., Crayle J; Department of Neurology, Washington University, St. Louis, MO, USA., Dimachkie M; Department of Neurology, University of Kansas, Kansas City, KS, USA., Ennist D; Origent Data Sciences, Inc, Vienna, VA, USA., Feldman E; Department of Neurology, University of Michigan, Ann Arbor, MI, USA., Fullam T; Department of Neurology, University of Texas, San Antonio, TX, USA., Heiman-Patterson T; Department of Neurology, Temple Health, Philadelphia, PA, USA., Jhooty S; University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Levine T; Bob Bove Neuroscience Institute, Scottsdale, AZ, USA., Li X; Department of Neurology, Duke University, Durham, NC, USA., Lund I; Green Hope High School, Cary, NC, USA., Mallon E; Duke University, Durham, NC, USA., Maragakis N; Department of Neurology, Johns Hopkins, Baltimore, MD, USA., McDermott C; Department of Neuroscience, University of Sheffield, Sheffield, UK., Pattee G; Department of Neurology, University of Nebraska Medical Center, Omaha, NE, USA., Pierce K; Department of Neuroscience, University of North Carolina, Chapel Hill, NC, USA., Ratner D; Tulane University, New Orleans, LA, USA., Staats K; Staats Life Consulting, Los Angeles, CA, USA., Wicks P; Independent Consultant, Lichfield, UK, and., Wiedau M; Department of Neurology, University of California, Los Angeles, CA, USA., Bedlack R; Department of Neurology, Duke University, Durham, NC, USA.
Jazyk: angličtina
Zdroj: Amyotrophic lateral sclerosis & frontotemporal degeneration [Amyotroph Lateral Scler Frontotemporal Degener] 2023 Jun 08, pp. 1-5. Date of Electronic Publication: 2023 Jun 08.
DOI: 10.1080/21678421.2023.2220742
Abstrakt: ALSUntangled reviews alternative and off-label treatments for people living with amyotrophic lateral sclerosis (PALS). Here, we review caffeine which has plausible mechanisms for slowing ALS progression. However, pre-clinical studies are contradictory, and a large case series showed no relationship between caffeine intake and ALS progression rate. While low doses of caffeine are safe and inexpensive, higher doses can cause serious side effects. At this time, we cannot endorse caffeine as a treatment to slow ALS progression.
Databáze: MEDLINE
Nepřihlášeným uživatelům se plný text nezobrazuje